Delcath Systems Swung to a Profit as Its Liver-Cancer Device Volume Grew 30%

Delcath Systems, which makes HEPZATO, a device-based system for delivering chemotherapy directly to the liver in patients with liver-dominant cancers, reported second-quarter 2026 earnings of $0.07 per share on August 6, 2026, against an estimate of a $0.09 loss — a swing from an expected loss to an actual profit. Revenue was $29.13 million versus $26.26 million expected. The stock rose 9.9% in the fifteen minutes after the release.

The swing to profitability was driven by real commercial growth rather than a one-time item: HEPZATO procedure volume grew approximately 30% year over year, meaning more patients received the treatment, not just favorable pricing or accounting. For a commercial-stage medical device company, procedure volume growth is the more durable signal than the earnings number itself, since it reflects adoption by treating physicians rather than a single quarter's financial mechanics. The company also reported $95.9 million in cash and investments as of June 30, 2026, and raised its full-year 2026 revenue guidance to a range of $104 million to $108 million.

Separately, independent investigators presented retrospective data at the ESMO Breast Cancer 2026 conference showing a 60% hepatic partial response rate using Delcath's percutaneous hepatic perfusion technique in heavily pretreated patients with liver-dominant metastatic breast cancer — a use case beyond the company's primary approved indication. Early retrospective data in a new tumor type is not the same as a completed clinical trial or a new approval, but it is the kind of signal that can expand a device's addressable patient population over time if it holds up in more rigorous study.